TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical, Ltd. (OTCQB: TOMDF) has appointed Billy Blanks as the first brand ambassador for its Tollovid® dietary supplement. Blanks, a renowned fitness icon, aims to raise awareness of Tollovid, which is a plant-based 3CL protease inhibitor. He has over 64,000 Instagram followers and 153,000 Facebook fans. Tollovid is not FDA-approved for treating COVID-19 but has received a Certificate of Free Sale. The CEO highlighted the importance of promoting immune support through this partnership, along with successful Phase 2 clinical trial results for the related drug, Tollovir.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its President and CEO, Gerald Commissiong, will present at the Proactive One2One Virtual Forum on March 17, 2022, from 2:00 PM to 2:30 PM ET. The company focuses on developing medical diagnostics for early detection of cancer, Alzheimer’s disease, and COVID-19. Todos operates a CLIA/CAP certified lab, Provista Diagnostics, and is preparing to launch its proprietary Videssa® breast cancer test. Additionally, it is involved in developing oral therapeutics for treating coronaviruses through its joint venture with NLC Pharma.

Todos Medical has formed a subsidiary, 3CL Pharma, aimed at developing and commercializing products related to 3CL protease, including Tollovir for COVID-19 treatment. This acquisition positions Todos as a leader in oral antivirals with key data indicating a 7.2-day reduction in hospitalization. Plans include global Emergency Use Authorization submissions and pivotal studies, enhancing market prospects. The team is led by Dr. Dorit Arad, who brings expertise in 3CL protease therapies, further solidifying the company’s growth trajectory in the evolving pandemic landscape.

Todos Medical, Ltd. (OTCQB: TOMDF) announced that its President and CEO Gerald Commissiong will present at the Emerging Growth Conference on March 16, 2022, from 1:30 pm to 2 pm EST. Todos Medical specializes in medical diagnostics aimed at early cancer detection and has recently expanded its services through the acquisition of Provista Diagnostics. The company's proprietary technology, Todos Biochemical Infrared Analyses, is designed to analyze blood for cancer indicators. For more details, visit www.todosmedical.com.

Todos Medical (OTCQB: TOMDF) has appointed Greg Meiselbach as Vice President of Government Affairs, aiming to promote the use of its antiviral products, including Tollovir™, to healthcare systems globally. Meiselbach's experience in biotechnology and government relations is expected to help position Tollovir as a crucial solution for alleviating hospital overutilization due to COVID-19.

CEO Gerald Commissiong emphasized that the new strategy involves 'Test to Treat' programs aimed at improving outpatient treatment for COVID patients, thus reducing hospitalization costs and the impact of Long COVID.

Todos Medical announced promising results from its early-closed Phase 2 trial of Tollovir™, an antiviral treatment for hospitalized COVID-19 patients. The primary endpoint, time to clinical improvement, was achieved with an average reduction of 2.7 days. Notably, there were 0% COVID-related deaths in the Tollovir group compared to 22% in the placebo group. The company plans a Phase 2/3 trial to pursue Emergency Use Authorization. This study's success could enhance hospital capacity during critical surges like with the Omicron variant.

Todos Medical, Ltd. (OTCQB: TOMDF) announced a data lock for the interim analysis of its Tollovir™ Phase 2 Clinical Trial, targeting severe/critical COVID-19 patients. Results are set to be disclosed on January 27, 2022. Dr. Dorit Arad, Chief Scientific Officer at NLC Pharma, expressed enthusiasm for the upcoming clinical trial data. Tollovir, a 3CL protease inhibitor, is designed to treat COVID-19 and has shown promise in in vitro studies. Todos aims to advance this therapeutic in critical medical use, alongside partnerships targeting expanded applications.

The 22nd Annual Celebrity Flag Football Challenge, presented by Todos Medical's Tollovid, will take place on February 12, 2022, at Pepperdine University in Malibu, California. The event features celebrity athletes, including Doug Flutie and Tracy McGrady, and aims to promote Tollovid's immune support benefits. Attendees can enjoy interactive games, food, and a halftime show. The game will be televised live on Bally Sports West and promoted by iHeartRadio. CEO Gerald Commissiong highlights the event's connection to Super Bowl weekend and Tollovid's presence on platforms like Amazon.

Todos Medical will sponsor the 22nd Annual Celebrity Flag Football Challenge® on February 12, 2022, in Malibu, California. This family-friendly event will feature a competitive football game with celebrities and athletes, supporting First Responders, Military Service Members, and Youth Groups. CEO Gerald Commissiong emphasized the opportunity to showcase Tollovid®, an all-natural immune support product, to the public. The event will be broadcast live and includes activities for all ages, enhancing community engagement while promoting health awareness.